ACRS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.94M

-78.96%

-0.142

-85.94%

2.30M

+58.08%

-0.150

+25%

2.33M

+30.84%

-0.140

+7.69%

Estimates Revision

The market is revising Upward the revenue expectations for Aclaris Therapeutics, Inc. (ACRS) for FY2025, with the revenue forecasts being adjusted by 40.89% over the past three months. During the same period, the stock price has changed by 37.44%.

Revenue Estimates for FY2025

Revise Upward

+40.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.82%

In Past 3 Month

Stock Price

Go Up

+37.44%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

9.25

High

16.00

Current: 0.000

Low

6.00

Averages

9.25

High

16.00

Piper Sandler

Biren Amin

Overweight

initiated

2025-07-09

Reason

Piper Sandler

Biren Amin

Price Target

2025-07-09

initiated

Overweight

Reason

Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics with an Overweight rating and $6 price target. The shares are currently trading below the company's cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers "meaningful upside" to Aclaris shares. Piper believes the company's lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis.

Wedbush

NULL -> Outperform

initiated

2025-05-28

Reason

Wedbush

Price Target

2025-05-28

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Aclaris Therapeutics with an Outperform rating and $8 price target.

Wedbush

Outperform

initiated

2025-05-28

Reason

Wedbush

Price Target

2025-05-28

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Aclaris Therapeutics with an Outperform rating and $8 price target. The firm notes Aclaris is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors generated with its KINect drug discovery platform, and in-licensed biologics for immunology and inflammation. A placebo-controlled Phase 2b trial in atopic dermatitis will begin in Q2 2025, with initial data in 2026. Topline results for the Phase 2 trial in AD are expected in June 2025, and Wedbush believes this readout is de-risked based on prior ITK inhibitor results. The firm views both data releases as key catalysts for shares, validating development in the sizeable AD market and drawing partnership interest for dermatology and respiratory expansions. Wedbush sees significant growth potential for Aclaris with two lead candidates offering "pipeline-in-a-product" opportunities following upcoming data readouts.

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$20 -> $16

2025-05-14

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$20 -> $16

2025-05-14

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Aclaris Therapeutics to $16 from $20 and keeps a Buy rating on the shares following the Q1 report.

Scotiabank

Louise Chen

Outperform

downgrade

$15 -> $9

2025-05-09

Reason

Scotiabank

Louise Chen

Price Target

$15 -> $9

2025-05-09

downgrade

Outperform

Reason

Scotiabank analyst Louise Chen lowered the firm's price target on Aclaris Therapeutics to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.

Cantor Fitzgerald

Prakhar Agrawal

Buy

Reiterates

n/a

2025-03-18

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

n/a

2025-03-18

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Aclaris Therapeutics Inc (ACRS.O) is -5.22, compared to its 5-year average forward P/E of -6.56. For a more detailed relative valuation and DCF analysis to assess Aclaris Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.56

Current PE

-5.22

Overvalued PE

-2.07

Undervalued PE

-11.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.70

Undervalued EV/EBITDA

-3.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

72.39

Current PS

35.11

Overvalued PS

134.72

Undervalued PS

10.05

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACRS News & Events

Events Timeline

No data

News

8.5

2025-12-19Globenewswire

Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025

4.5

2025-12-19Yahoo Finance

Aclaris Therapeutics Added to Nasdaq Biotechnology Index

8.5

2025-12-19Newsfilter

Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025

People Also Watch

Frequently Asked Questions

What is Aclaris Therapeutics Inc (ACRS) stock price today?

The current price of ACRS is 2.68 USD — it has increased 0 % in the last trading day.

What is Aclaris Therapeutics Inc (ACRS)'s business?

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

What is the price predicton of ACRS Stock?

What is Aclaris Therapeutics Inc (ACRS)'s revenue for the last quarter?

Aclaris Therapeutics Inc revenue for the last quarter amounts to 3.30M USD, decreased -24.09 % YoY.

What is Aclaris Therapeutics Inc (ACRS)'s earnings per share (EPS) for the last quarter?

Aclaris Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, increased 9.09 % YoY.

What changes have occurred in the market's expectations for Aclaris Therapeutics Inc (ACRS)'s fundamentals?

How many employees does Aclaris Therapeutics Inc (ACRS). have?

Aclaris Therapeutics Inc (ACRS) has 64 emplpoyees as of January 09 2026.

What is Aclaris Therapeutics Inc (ACRS) market cap?

Today ACRS has the market capitalization of 290.37M USD.